Raymond Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 21, 2025, 12:27 pm

Competitors of Raymond Ltd

All Competitor Stocks of Raymond Ltd

Quarterly Result

Last Updated: May 31, 2025, 7:58 am

Below is a detailed analysis of the quarterly data for Raymond Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 557.00 Cr.. The value appears strong and on an upward trend. It has increased from 466.00 Cr. (Dec 2024) to 557.00 Cr., marking an increase of 91.00 Cr..
• For Expenses, as of Mar 2025, the value is 513.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 435.00 Cr. (Dec 2024) to 513.00 Cr., marking an increase of 78.00 Cr..
• For Operating Profit, as of Mar 2025, the value is 44.00 Cr.. The value appears strong and on an upward trend. It has increased from 31.00 Cr. (Dec 2024) to 44.00 Cr., marking an increase of 13.00 Cr..
• For OPM %, as of Mar 2025, the value is 8.00%. The value appears strong and on an upward trend. It has increased from 7.00% (Dec 2024) to 8.00%, marking an increase of 1.00%.
• For Other Income, as of Mar 2025, the value is 156.00 Cr.. The value appears strong and on an upward trend. It has increased from 95.00 Cr. (Dec 2024) to 156.00 Cr., marking an increase of 61.00 Cr..
• For Interest, as of Mar 2025, the value is 17.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 16.00 Cr. (Dec 2024) to 17.00 Cr., marking an increase of 1.00 Cr..
• For Depreciation, as of Mar 2025, the value is 37.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 37.00 Cr..
• For Profit before tax, as of Mar 2025, the value is 146.00 Cr.. The value appears strong and on an upward trend. It has increased from 73.00 Cr. (Dec 2024) to 146.00 Cr., marking an increase of 73.00 Cr..
• For Tax %, as of Mar 2025, the value is 6.00%. The value appears to be increasing, which may not be favorable. It has increased from 1.00% (Dec 2024) to 6.00%, marking an increase of 5.00%.
• For Net Profit, as of Mar 2025, the value is 137.00 Cr.. The value appears strong and on an upward trend. It has increased from 72.00 Cr. (Dec 2024) to 137.00 Cr., marking an increase of 65.00 Cr..
• For EPS in Rs, as of Mar 2025, the value is 19.93. The value appears strong and on an upward trend. It has increased from 10.83 (Dec 2024) to 19.93, marking an increase of 9.10.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: May 15, 2025, 5:27 am

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: May 13, 2025, 2:50 pm

Below is a detailed analysis of the balance sheet data for Raymond Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 67.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 67.00 Cr..
• For Reserves, as of Mar 2025, the value is 3,650.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,551.00 Cr. (Mar 2024) to 3,650.00 Cr., marking a decrease of 901.00 Cr..
• For Borrowings, as of Mar 2025, the value is 740.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 4,181.00 Cr. (Mar 2024) to 740.00 Cr., marking a decrease of 3,441.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 3,260.00 Cr.. The value appears to be improving (decreasing). It has decreased from 4,203.00 Cr. (Mar 2024) to 3,260.00 Cr., marking a decrease of 943.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 7,716.00 Cr.. The value appears to be improving (decreasing). It has decreased from 13,001.00 Cr. (Mar 2024) to 7,716.00 Cr., marking a decrease of 5,285.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,778.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,475.00 Cr. (Mar 2024) to 1,778.00 Cr., marking a decrease of 1,697.00 Cr..
• For CWIP, as of Mar 2025, the value is 5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 99.00 Cr. (Mar 2024) to 5.00 Cr., marking a decrease of 94.00 Cr..
• For Investments, as of Mar 2025, the value is 1,120.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,826.00 Cr. (Mar 2024) to 1,120.00 Cr., marking a decrease of 1,706.00 Cr..
• For Other Assets, as of Mar 2025, the value is 4,814.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6,601.00 Cr. (Mar 2024) to 4,814.00 Cr., marking a decrease of 1,787.00 Cr..
• For Total Assets, as of Mar 2025, the value is 7,716.00 Cr.. The value appears to be declining and may need further review. It has decreased from 13,001.00 Cr. (Mar 2024) to 7,716.00 Cr., marking a decrease of 5,285.00 Cr..

Notably, the Reserves (3,650.00 Cr.) exceed the Borrowings (740.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Raymond Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 1,146.69. This value is within the healthy range. It has increased from 246.07 (Mar 24) to 1,146.69, marking an increase of 900.62.
• For Diluted EPS (Rs.), as of Mar 25, the value is 1,145.99. This value is within the healthy range. It has increased from 246.07 (Mar 24) to 1,145.99, marking an increase of 899.92.
• For Cash EPS (Rs.), as of Mar 25, the value is 1,176.08. This value is within the healthy range. It has increased from 140.27 (Mar 24) to 1,176.08, marking an increase of 1,035.81.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 558.40. It has decreased from 759.60 (Mar 24) to 558.40, marking a decrease of 201.20.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 558.40. It has decreased from 759.60 (Mar 24) to 558.40, marking a decrease of 201.20.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 292.54. It has decreased from 1,355.27 (Mar 24) to 292.54, marking a decrease of 1,062.73.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 50.31. This value is within the healthy range. It has decreased from 236.69 (Mar 24) to 50.31, marking a decrease of 186.38.
• For PBIT / Share (Rs.), as of Mar 25, the value is 28.35. This value is within the healthy range. It has decreased from 194.06 (Mar 24) to 28.35, marking a decrease of 165.71.
• For PBT / Share (Rs.), as of Mar 25, the value is 18.54. This value is within the healthy range. It has decreased from 131.10 (Mar 24) to 18.54, marking a decrease of 112.56.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 1,154.12. This value is within the healthy range. It has increased from 97.64 (Mar 24) to 1,154.12, marking an increase of 1,056.48.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 1,146.71. This value is within the healthy range. It has increased from 246.09 (Mar 24) to 1,146.71, marking an increase of 900.62.
• For PBDIT Margin (%), as of Mar 25, the value is 17.19. This value is within the healthy range. It has decreased from 17.46 (Mar 24) to 17.19, marking a decrease of 0.27.
• For PBIT Margin (%), as of Mar 25, the value is 9.69. This value is below the healthy minimum of 10. It has decreased from 14.31 (Mar 24) to 9.69, marking a decrease of 4.62.
• For PBT Margin (%), as of Mar 25, the value is 6.33. This value is below the healthy minimum of 10. It has decreased from 9.67 (Mar 24) to 6.33, marking a decrease of 3.34.
• For Net Profit Margin (%), as of Mar 25, the value is 394.52. This value exceeds the healthy maximum of 10. It has increased from 7.20 (Mar 24) to 394.52, marking an increase of 387.32.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 391.98. This value exceeds the healthy maximum of 20. It has increased from 18.15 (Mar 24) to 391.98, marking an increase of 373.83.
• For Return on Networth / Equity (%), as of Mar 25, the value is 205.35. This value is within the healthy range. It has increased from 35.46 (Mar 24) to 205.35, marking an increase of 169.89.
• For Return on Capital Employeed (%), as of Mar 25, the value is 4.01. This value is below the healthy minimum of 10. It has decreased from 14.79 (Mar 24) to 4.01, marking a decrease of 10.78.
• For Return On Assets (%), as of Mar 25, the value is 98.89. This value is within the healthy range. It has increased from 12.43 (Mar 24) to 98.89, marking an increase of 86.46.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 0.2. It has decreased from 0.51 (Mar 24) to 0.07, marking a decrease of 0.44.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.18. This value is within the healthy range. It has decreased from 0.74 (Mar 24) to 0.18, marking a decrease of 0.56.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.18. It has decreased from 0.84 (Mar 24) to 0.18, marking a decrease of 0.66.
• For Current Ratio (X), as of Mar 25, the value is 1.73. This value is within the healthy range. It has increased from 1.66 (Mar 24) to 1.73, marking an increase of 0.07.
• For Quick Ratio (X), as of Mar 25, the value is 1.59. This value is within the healthy range. It has increased from 0.87 (Mar 24) to 1.59, marking an increase of 0.72.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.35. This value is below the healthy minimum of 4. It has decreased from 0.51 (Mar 24) to 0.35, marking a decrease of 0.16.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 1.21 (Mar 24) to 0.00, marking a decrease of 1.21.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 1.03 (Mar 24) to 0.00, marking a decrease of 1.03.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 98.79 (Mar 24) to 0.00, marking a decrease of 98.79.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 98.97 (Mar 24) to 0.00, marking a decrease of 98.97.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 5.13. This value is within the healthy range. It has increased from 4.19 (Mar 24) to 5.13, marking an increase of 0.94.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.49. This value is below the healthy minimum of 3. It has decreased from 2.84 (Mar 24) to 2.49, marking a decrease of 0.35.
• For Enterprise Value (Cr.), as of Mar 25, the value is 10,159.96. It has decreased from 15,373.68 (Mar 24) to 10,159.96, marking a decrease of 5,213.72.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.22. This value exceeds the healthy maximum of 3. It has increased from 1.70 (Mar 24) to 5.22, marking an increase of 3.52.
• For EV / EBITDA (X), as of Mar 25, the value is 30.35. This value exceeds the healthy maximum of 15. It has increased from 9.76 (Mar 24) to 30.35, marking an increase of 20.59.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.80. This value exceeds the healthy maximum of 3. It has increased from 1.33 (Mar 24) to 4.80, marking an increase of 3.47.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 98.78 (Mar 24) to 0.00, marking a decrease of 98.78.
• For Price / BV (X), as of Mar 25, the value is 2.51. This value is within the healthy range. It has decreased from 2.61 (Mar 24) to 2.51, marking a decrease of 0.10.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.80. This value exceeds the healthy maximum of 3. It has increased from 1.33 (Mar 24) to 4.80, marking an increase of 3.47.
• For EarningsYield, as of Mar 25, the value is 0.81. This value is below the healthy minimum of 5. It has increased from 0.13 (Mar 24) to 0.81, marking an increase of 0.68.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness